|
|
|
|
Program |
|
F. I. CarrollShort curriculum vitae
Dr. Carroll
is a longstanding member of the American Chemical Society, is a Fellow
of the AAAS and the AAPS, and is a member of a number of other
professional organizations. His activities include service on the
Long-Range Planning Committee of the Medicinal Chemistry Section of the
American Chemical Society as well as service on the American Chemical
Society Awards Committee. He served on the Editorial Advisory Board of
the Journal of Medicinal Chemistry
from 1995–1999 and is presently Medicinal Chemistry Section Editor for
Drug Development Research. For
many years he has provided service and advice to the National Institute
on Drug Abuse and has been a member of several study sections. Dr. Carroll
has won national and international recognition as a medicinal chemist
who has made distinguished contributions to many research areas, in
particular the development of the 3-phenyltropane class of compounds as
potential treatment agents for cocaine abuse. One of the 3-phenyltropane
analogs (RTI-55) is also in phase III clinical trial as a diagnostic
agent for Parkinson's disease. In his effort to develop agents for
treating and preventing drug abuse, he has applied combinatorial methods
in developing new structural types of opioid kappa receptor-selective
antagonists and recently developed new nicotinic receptor antagonists. Dr.
Carroll's research efforts have resulted in 359 scientific publications
and 18 patents. He has trained 79 postdoctoral fellows. Among Dr.
Carroll's awards are the Distinguished Lecturer Award from the North
Carolina Section of the American Chemical Society (1993), the Herty
Medal (2001), and the Southern Chemist Award (2000). In addition, Dr.
Carroll was honored by the National Institute of Drug Abuse with the
1993 Pacesetter Award and a 1996 MERIT Award for his research on the
biochemical mechanisms of the action of cocaine. |
© 28th National Chemistry Symposium, 2001-02